Ubiquitin-Proteasome Dynamics in Neurodegenerative Disorders

The ubiquitin–proteasome system (UPS) serves as the principal mechanism for targeted protein turnover in eukaryotic cells, tagging misfolded or excess proteins with ubiquitin and directing them to the proteasome for degradation. In neurons, the precision of this pathway underpins synaptic plasticity and the long-term maintenance of cellular homeostasis. Dysregulation of ubiquitination or proteasomal function permits the accumulation of aggregation-prone proteins, a hallmark of disorders such as Alzheimer’s, Parkinson’s and Huntington’s diseases. Aberrant UPS activity not only fosters toxic inclusion bodies but also perturbs mitochondrial quality control, axonal transport and neurotrophic signalling. Recent advances reveal intimate crosstalk between the UPS and other clearance pathways—most notably autophagy—and uncover adaptive responses to proteotoxic stress involving antioxidant defences and compensatory changes in neurotransmitter systems. A clearer understanding of the dynamic regulation of protein ubiquitination, proteasomal capacity and their failure in vulnerable neuronal populations is now guiding the development of both diagnostic biomarkers and novel therapeutic strategies aimed at restoring proteostasis in the ageing brain.

Research from Nature Portfolio

Longitudinal in vivo imaging of chronic proteasome inhibition in a large-animal model has revealed early changes in monoaminergic projections that mirror prodromal features of Parkinson’s disease. Using PET ligands for vesicular monoamine transporter type 2 and α2-adrenoceptors, researchers demonstrated dose-dependent declines in striatal dopaminergic markers alongside compensatory increases in noradrenergic binding in key brain regions. A subset of animals imaged for serotonin transporter density and microglial activation further exhibited reduced serotonergic tone and heightened neuroinflammation. These findings underscore how sub-clinical UPS impairment can precipitate network-level neurotransmitter adaptations and glial responses, offering a translational platform for testing interventions that bolster proteasomal function or target early synaptic alterations.

Ubiquitin-Proteasome Dynamics in Neurodegenerative Disorders publication trend

The graph below shows the total number of articles in ubiquitin-proteasome dynamics in neurodegenerative disorders across all publications each year (not limited to Nature Index journals).

Technical terms

Ubiquitin: A small regulatory protein that is covalently attached to substrates to mark them for proteasomal degradation or other cellular fates.

Proteasome: A large, multi-subunit protease complex responsible for the ATP-dependent degradation of ubiquitinated proteins, crucial for maintaining protein homeostasis.

Ubiquitin-proteasome system (UPS): The coordinated cellular pathway that tags proteins with ubiquitin and delivers them to the proteasome, regulating protein quality, quantity and function.

Proteasome inhibitor: A molecule that blocks proteasomal protease activity, often used experimentally to model UPS impairment and study downstream cellular consequences.

References

1. Dysregulation of Ubiquitin-Proteasome System in Neurodegenerative Diseases. Frontiers in Aging Neuroscience (2016).
2. Longitudinal monoaminergic PET imaging of chronic proteasome inhibition in minipigs. Scientific Reports (2018).
3. The Effect of Neurotoxin MPTP and Neuroprotector Isatin on the Profile of Ubiquitinated Brain Mitochondrial Proteins. Cells (2018).
4. Antagonism of proteasome inhibitor-induced heme oxygenase-1 expression by PINK1 mutation. PLOS ONE (2017).